YU91802A - Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata - Google Patents
Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijataInfo
- Publication number
- YU91802A YU91802A YU91802A YUP91802A YU91802A YU 91802 A YU91802 A YU 91802A YU 91802 A YU91802 A YU 91802A YU P91802 A YUP91802 A YU P91802A YU 91802 A YU91802 A YU 91802A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- azabicyclo
- opiate
- pharmaceutically
- opioid receptor
- useful
- Prior art date
Links
- 108090000137 Opioid Receptors Proteins 0.000 title abstract 3
- 102000003840 Opioid Receptors Human genes 0.000 title abstract 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 title 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 206010003645 Atopy Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010012434 Dermatitis allergic Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000012488 Opiate Overdose Diseases 0.000 abstract 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 108700023159 delta Opioid Receptors Proteins 0.000 abstract 1
- 102000048124 delta Opioid Receptors Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract 1
- 102000051367 mu Opioid Receptors Human genes 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000001823 pruritic effect Effects 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
- 108020001588 κ-opioid receptors Proteins 0.000 abstract 1
- 108020001612 μ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Jedinjenja formule (I) gde su supstituenti definisani u opisu, i njegovi farmaceutski ili veterinarski prihvatljivi derivati, korisni su farmaceutski i veterinarski, naročito zato što se vežu za receptore opijata (npr. mi, kapa i delta receptore opijata). Oni su pogodni za upotrebu u tretmanu bolesti ili stanja posredovanih receptorima opijata, kao što su na primer sindrom iritabilne utrobe; konstipacija; mučnina; povraćanje; prirutičke dermatoze, kao što su alergijski dermatitis i atopija; poremećaji u ishrani; prekomerno uzimanje opijata; depresija; zavisnost od pušenja i alkohola; seksualna disfunkcija; šok; šlog; povreda kičme; i trauma glave.[Compounds of formula (I), where the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof, are pharmaceutically and veterinarily useful, in particular they bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). They are likely to be useful in the treatment of diseases or conditions modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; pruritic dermatoses, such as allergic dermatitis and atopy; eating disorders; opiate overdoses; depression; smoking and alcohol addiction; sexual dysfunction; shock; stroke; spinal damage; and head trauma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015562.2A GB0015562D0 (en) | 2000-06-23 | 2000-06-23 | Heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU91802A true YU91802A (sh) | 2006-05-25 |
Family
ID=9894368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU91802A YU91802A (sh) | 2000-06-23 | 2001-06-07 | Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1292574A1 (sh) |
| JP (1) | JP2004512263A (sh) |
| KR (1) | KR20040002386A (sh) |
| CN (1) | CN1639121A (sh) |
| AP (1) | AP2002002698A0 (sh) |
| AR (1) | AR028969A1 (sh) |
| AU (1) | AU781837B2 (sh) |
| BG (1) | BG107329A (sh) |
| BR (1) | BR0111867A (sh) |
| CA (1) | CA2412188A1 (sh) |
| CZ (1) | CZ20023967A3 (sh) |
| DO (1) | DOP2001000187A (sh) |
| DZ (1) | DZ3368A1 (sh) |
| EA (1) | EA005117B1 (sh) |
| GB (1) | GB0015562D0 (sh) |
| HR (1) | HRP20020998A2 (sh) |
| HU (1) | HUP0301228A3 (sh) |
| IL (1) | IL153427A0 (sh) |
| IS (1) | IS6637A (sh) |
| MA (1) | MA26915A1 (sh) |
| MX (1) | MXPA02012878A (sh) |
| NO (1) | NO20026168L (sh) |
| NZ (1) | NZ523141A (sh) |
| OA (1) | OA12293A (sh) |
| PA (1) | PA8519401A1 (sh) |
| PE (1) | PE20020253A1 (sh) |
| PL (1) | PL365956A1 (sh) |
| SK (1) | SK17172002A3 (sh) |
| TN (1) | TNSN01094A1 (sh) |
| UA (1) | UA73176C2 (sh) |
| UY (1) | UY26787A1 (sh) |
| WO (1) | WO2001098267A1 (sh) |
| YU (1) | YU91802A (sh) |
| ZA (1) | ZA200210278B (sh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006708B1 (ru) * | 2001-10-22 | 2006-02-24 | Пфайзер Продактс Инк. | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора |
| WO2003097051A2 (en) * | 2002-05-17 | 2003-11-27 | Merck Patent Gmbh | Use of compounds that are effective as selective opiate receptor modulators |
| DE10259245A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| PT1745040E (pt) | 2004-02-23 | 2010-03-08 | Glaxo Group Ltd | Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| EP1891056B1 (en) * | 2005-06-14 | 2010-10-13 | Glaxo Group Limited | Novel compounds |
| WO2007113258A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| CA2682608A1 (en) | 2007-03-30 | 2008-10-09 | Tioga Pharmaceuticals, Inc. | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome |
| TWI423801B (zh) * | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物 |
| EP2580201B1 (en) | 2010-06-11 | 2017-08-02 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| BR112013007566A2 (pt) | 2010-09-28 | 2016-08-02 | Panacea Biotec Ltd | novos compostos bicíclicos |
| CN105764888B (zh) * | 2013-11-20 | 2018-04-06 | 株式会社三和化学研究所 | 一种新的3‑氮杂双环[3.1.0]己烷衍生物以及其医药用途 |
| CN107428687B (zh) | 2015-05-20 | 2021-06-11 | 宇部兴产株式会社 | 一种3-氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用 |
| CN110446495B (zh) | 2017-02-17 | 2023-09-05 | 特维娜有限公司 | 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 |
| AU2018221148B2 (en) | 2017-02-17 | 2022-05-05 | Trevena, Inc. | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
| JPWO2018159716A1 (ja) | 2017-03-02 | 2019-12-26 | 株式会社三和化学研究所 | アルコール使用障害の治療薬 |
| CN108250088B (zh) * | 2018-01-04 | 2020-10-30 | 四川之江高新材料股份有限公司 | N，n，n′-三甲基-n′-羟乙基双氨基乙基醚的制备方法 |
| CN115825305B (zh) * | 2022-10-21 | 2024-09-20 | 昆明理工大学 | 一种分子印迹固相微萃取纤维及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065230A (en) * | 1959-03-16 | 1962-11-20 | Burroughs Wellcome Co | Azabicyclohexanes and method of preparing them |
| DE3851081T2 (de) * | 1987-04-16 | 1995-02-16 | Lilly Co Eli | Piperidine als Opioid-Antagoniste. |
| US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
| DE4341403A1 (de) * | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| TWI244481B (en) * | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
-
2000
- 2000-06-23 GB GBGB0015562.2A patent/GB0015562D0/en not_active Ceased
-
2001
- 2001-06-06 DO DO2001000187A patent/DOP2001000187A/es unknown
- 2001-06-07 HU HU0301228A patent/HUP0301228A3/hu unknown
- 2001-06-07 JP JP2002504223A patent/JP2004512263A/ja not_active Withdrawn
- 2001-06-07 EP EP01936728A patent/EP1292574A1/en not_active Withdrawn
- 2001-06-07 OA OA1200200386A patent/OA12293A/en unknown
- 2001-06-07 DZ DZ013368A patent/DZ3368A1/xx active
- 2001-06-07 KR KR1020027017503A patent/KR20040002386A/ko not_active Ceased
- 2001-06-07 CA CA002412188A patent/CA2412188A1/en not_active Abandoned
- 2001-06-07 NZ NZ523141A patent/NZ523141A/en unknown
- 2001-06-07 PL PL01365956A patent/PL365956A1/xx not_active Application Discontinuation
- 2001-06-07 HR HR20020998A patent/HRP20020998A2/hr not_active Application Discontinuation
- 2001-06-07 MX MXPA02012878A patent/MXPA02012878A/es unknown
- 2001-06-07 SK SK1717-2002A patent/SK17172002A3/sk unknown
- 2001-06-07 IL IL15342701A patent/IL153427A0/xx unknown
- 2001-06-07 YU YU91802A patent/YU91802A/sh unknown
- 2001-06-07 AU AU62591/01A patent/AU781837B2/en not_active Ceased
- 2001-06-07 CN CNA018116086A patent/CN1639121A/zh active Pending
- 2001-06-07 AP APAP/P/2002/002698A patent/AP2002002698A0/en unknown
- 2001-06-07 EA EA200201269A patent/EA005117B1/ru not_active IP Right Cessation
- 2001-06-07 WO PCT/IB2001/001035 patent/WO2001098267A1/en not_active Ceased
- 2001-06-07 CZ CZ20023967A patent/CZ20023967A3/cs unknown
- 2001-06-07 BR BR0111867-6A patent/BR0111867A/pt not_active IP Right Cessation
- 2001-06-12 PA PA20018519401A patent/PA8519401A1/es unknown
- 2001-06-21 AR ARP010102957A patent/AR028969A1/es unknown
- 2001-06-21 PE PE2001000604A patent/PE20020253A1/es not_active Application Discontinuation
- 2001-06-21 UY UY26787A patent/UY26787A1/es not_active Application Discontinuation
- 2001-06-22 TN TNTNSN01094A patent/TNSN01094A1/fr unknown
- 2001-07-06 UA UA20021210406A patent/UA73176C2/uk unknown
-
2002
- 2002-11-28 IS IS6637A patent/IS6637A/is unknown
- 2002-11-28 BG BG107329A patent/BG107329A/xx unknown
- 2002-12-16 MA MA26955A patent/MA26915A1/fr unknown
- 2002-12-19 ZA ZA200210278A patent/ZA200210278B/xx unknown
- 2002-12-20 NO NO20026168A patent/NO20026168L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU91802A (sh) | Derivati 3-azabiciklo(3.1.0.)heksana koji imaju afinitet prema receptoru opijata | |
| WO2005080343A3 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
| TW200503713A (en) | Novel compounds | |
| WO2007095223A3 (en) | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases | |
| MY138478A (en) | Benzazepine derivatives for the treatment of neurological disorders | |
| TW200505921A (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | |
| UA84930C2 (ru) | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения | |
| GEP20043366B (en) | Benzothiophene Derivative Compounds Process of Preparation and Use Thereof | |
| WO2009125923A3 (en) | Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | |
| WO2007078523A3 (en) | 5-phenyl-3-benzyl-0xaz0lidin-2-0ne derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders | |
| WO2006116218A8 (en) | Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride | |
| TW200514781A (en) | Novel compounds | |
| MA29623B1 (fr) | Derives de pyrazolo [3, 4-d] azepine comme antagonistes d'histamine h3 | |
| DE602004024188D1 (de) | Des opioid-rezeptors | |
| WO2006067428A3 (en) | 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands | |
| EP1725536B8 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| WO2002011732A8 (en) | Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists | |
| WO2004089908A3 (en) | 3-azabicyclo[3.2.1]octane derivatives | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| WO2002059127A3 (en) | Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists | |
| WO2004050616A3 (en) | Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines | |
| AU2007288444A8 (en) | Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane | |
| WO2005035504A3 (en) | 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders | |
| WO2006029210A3 (en) | Acyclic 1,3-diamines and uses therefor | |
| UA81464C2 (en) | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS |